[A23-95] Pegunigalsidase alfa (Fabry disease) – Benefit assessment according to §35a Social Code Book V
Last updated 21.03.2024
Project no.:
A23-95
Commission:
Commission awarded on 29.10.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-95_en
| Project no. | Title | Status |
|---|---|---|
| A24-21 | Pegunigalsidase alfa (Fabry disease) – Addendum to Project A23-95 | Commission completed |
Federal Joint Committee (G-BA)
2024-03-21 A G-BA decision was published.